ARS Pharmaceuticals, Inc. (SPRY)
5.80
+0.03
(+0.52%)
USD |
NASDAQ |
Sep 02, 16:00
5.80
0.00 (0.00%)
After-Hours: 19:31
ARS Pharmaceuticals Research and Development Expense (Annual) : 13.18M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 13.18M |
| December 31, 2024 | 19.58M |
| December 31, 2023 | 20.27M |
| December 31, 2022 | 18.38M |
| Date | Value |
|---|---|
| December 31, 2021 | 20.27M |
| December 31, 2020 | 23.94M |
| December 31, 2019 | 21.50M |
| December 31, 2018 | 14.80M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Passage Bio, Inc. | 23.28M |
| Vertex Pharmaceuticals, Inc. | 3.754B |
| Capricor Therapeutics, Inc. | 83.50M |
| Kyntra Bio, Inc. | 23.52M |
| Zentalis Pharmaceuticals, Inc. | 107.30M |